ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study

PURPOSE: ARRY-382 (PF-07265804) is a selective inhibitor of colony-stimulating factor-1 receptor. We evaluated the safety and preliminary efficacy of ARRY-382 plus pembrolizumab in patients with advanced solid tumors. PATIENTS AND METHODS: This was an open-label, multicenter, Phase 1b/2 study (NCT02...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Melissa, Dudek, Arkadiusz Z., Sukari, Ammar, Call, Justin, Kunk, Paul R., Lewis, Karl, Gainor, Justin F., Sarantopoulos, John, Lee, Patrice, Golden, Adele, Harney, Allison, Rothenberg, S. Michael, Zhang, Yuanyuan, Goldman, Jonathan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359741/
https://www.ncbi.nlm.nih.gov/pubmed/35302585
http://dx.doi.org/10.1158/1078-0432.CCR-21-3009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359741/
https://www.ncbi.nlm.nih.gov/pubmed/35302585
http://dx.doi.org/10.1158/1078-0432.CCR-21-3009

Ejemplares similares